[Anticoagulation and antiaggregation in neurological patients]

Area of Science:

• Neurology
• Pharmacology
• Cardiovascular Medicine

Background:

• Stroke management requires careful drug selection based on etiology and patient factors.
• Antiplatelet agents and anticoagulants play crucial roles in acute stroke and secondary prevention.
• Understanding specific indications for different anticoagulants and antiplatelet therapies is vital.

Purpose of the Study:

• To outline the current therapeutic strategies for acute stroke and recurrent stroke prevention.
• To detail the appropriate use of aspirin, heparin, clopidogrel, dipyridamole, and warfarin.
• To clarify indications for anticoagulation in specific cerebrovascular conditions.

Main Methods:

• Review of established guidelines and clinical evidence for stroke pharmacotherapy.
• Analysis of drug efficacy in different stroke subtypes and etiological categories.
• Comparison of antiplatelet and anticoagulant therapies for secondary stroke prevention.

Main Results:

• Aspirin is the primary agent for acute ischemic stroke when thrombolysis is contraindicated.
• Heparin use is restricted to specific acute stroke scenarios like cerebral venous thrombosis or arterial dissection.
• Warfarin demonstrates efficacy in preventing stroke in atrial fibrillation, cerebral venous thrombosis, and antiphospholipid antibody syndrome.

Conclusions:

• Antiplatelet agents, particularly aspirin, are foundational for preventing recurrent noncardioembolic ischemic stroke.
• Combination therapy (aspirin/dipyridamole) or clopidogrel may be used for high-risk patients.
• Warfarin is indicated for specific conditions and its use in other cerebrovascular diseases requires further evidence.